Reviva Pharmaceuticals Holdings, Inc. (RVPH) stock
RVPHOTCPharmaceutical PreparationsFiscal year ends December 31
$0.45−0.02 (-4.36%)
Close on Oct 19, 2026Market cap $5.94MP/E –Yield –
Reviva Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Reviva Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2026 was $5.77M, down 60.6% year over year. For fiscal 2025 it was $11.71M, down 48.9% from the year before. The highest annual figure on record is $31.42M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.71M | -48.9% |
| FY2024 | Dec 31, 2024 | $22.91M | -27.1% |
| FY2023 | Dec 31, 2023 | $31.42M | +37.4% |
| FY2022 | Dec 31, 2022 | $22.87M | +371.4% |
| FY2021 | Dec 31, 2021 | $4.85M | +1543.8% |
| FY2020 | Dec 31, 2020 | $295.15K | +50.8% |
| FY2019 | Dec 31, 2019 | $195.74K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.20M | -43.8% |
| Q2 FY2026 | Jun 30, 2026 | $1.39M | -62.6% |
| Q1 FY2026 | Mar 31, 2026 | $1.44M | -65.1% |
| Q4 FY2025 | Dec 31, 2025 | $1.74M | -62.8% |
| Q3 FY2025 | Sep 30, 2025 | $2.13M | -68.9% |
| Q2 FY2025 | Jun 30, 2025 | $3.72M | -33.3% |
| Q1 FY2025 | Mar 31, 2025 | $4.11M | -28.9% |
| Q4 FY2024 | Dec 31, 2024 | $4.68M | -42.3% |
| Q3 FY2024 | Sep 30, 2024 | $6.86M | -28.4% |
| Q2 FY2024 | Jun 30, 2024 | $5.58M | -32.4% |
| Q1 FY2024 | Mar 31, 2024 | $5.78M | +5.5% |
| Q4 FY2023 | Dec 31, 2023 | $8.11M | +9.3% |
| Q3 FY2023 | Sep 30, 2023 | $9.57M | +125.7% |
| Q2 FY2023 | Jun 30, 2023 | $8.26M | +82.9% |
| Q1 FY2023 | Mar 31, 2023 | $5.48M | -5.9% |
| Q4 FY2022 | Dec 31, 2022 | $7.42M | +178.5% |
| Q3 FY2022 | Sep 30, 2022 | $4.24M | +198.0% |
| Q2 FY2022 | Jun 30, 2022 | $4.51M | +1106.0% |
| Q1 FY2022 | Mar 31, 2022 | $5.83M | +1390.4% |
| Q4 FY2021 | Dec 31, 2021 | $2.66M | – |
| Q3 FY2021 | Sep 30, 2021 | $1.42M | – |
| Q2 FY2021 | Jun 30, 2021 | $374.33K | – |
| Q1 FY2021 | Mar 31, 2021 | $391.16K | – |
See a number that looks wrong?